Using chemobiosynthesis and synthetic mini-polyketide synthases to produce pharmaceutical intermediates in Escherichia coli

Kosan Biosciences Inc., Hayward, California 94545, USA.
Applied and Environmental Microbiology (Impact Factor: 3.95). 08/2010; 76(15):5221-7. DOI: 10.1128/AEM.02961-09
Source: PubMed

ABSTRACT Recombinant microbial whole-cell biocatalysis is a valuable approach for producing enantiomerically pure intermediates for the synthesis of complex molecules. Here, we describe a method to produce polyketide intermediates possessing multiple stereogenic centers by combining chemobiosynthesis and engineered mini-polyketide synthases (PKSs). Chemobiosynthesis allows the introduction of unnatural moieties, while a library of synthetic bimodular PKSs expressed from codon-optimized genes permits the introduction of a variety of ketide units. To validate the approach, intermediates for the synthesis of trans-9,10-dehydroepothilone D were generated. The designer molecules obtained have the potential to greatly reduce the manufacturing cost of epothilone analogues, thus facilitating their commercial development as therapeutic agents.

Download full-text


Available from: John R Carney, Jan 23, 2014
1 Follower
  • [Show abstract] [Hide abstract]
    ABSTRACT: Antibiotics and mycotoxins share many remarkable similarities in structure, metabolic roles and biosynthesis, indicating their differences are primarily in the minds and economies of man, not the perspectives of producing organisms. Antibiotic/mycotoxin biosynthetic gene packages appear to have been assembled by transposon-mediated processes combining genes acquired horizontally from plants and other soil microbes with genes from the producing organism’s own genome. Probable gene sources include those for the synthesis and secretion of plant phytoalexins, toxins, allelochemicals, pheromones, germination inhibitors and pigments, and bacterial quorum-sensors and siderophores. Understanding antibiotic origins may assist in the discovery and creation of new antibiotics.
    Toxin Reviews 01/2011; 30(1):6-30. DOI:10.3109/15569543.2011.550862 · 0.84 Impact Factor
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Bacteria have long been used for the synthesis of a wide range of useful proteins and compounds. The developments of new bioprocesses and improvements of existing strategies for syntheses of valuable products in various bacterial cell hosts have their own challenges and limitations. The field of synthetic biology has combined knowledge from different science and engineering disciplines and facilitated the advancement of novel biological components which has inspired the design of targeted biosynthesis. Here we discuss recent advances in synthetic biology with relevance to biosynthesis in bacteria and the applications of computational algorithms and tools for manipulation of cellular components. Continuous improvements are necessary to keep up with increasing demands in terms of complexity, scale, and predictability of biosynthesis products.
    FEBS letters 02/2012; 586(15):2184-90. DOI:10.1016/j.febslet.2012.02.030 · 3.34 Impact Factor
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: PKS biocatalysis: The terminal module of erythromycin synthase was used for the in vitro production of chiral triketide lactones. Combining cofactor regeneration, substrate truncation, and enzymatic promiscuity afforded a scalable strategy to generate these molecules from abundant racemic and achiral precursors. The described biocatalytic platform thus facilitates the application and study of enzymes within PKS modules.
    ChemBioChem 10/2012; 13(15):2200-3. DOI:10.1002/cbic.201200378 · 3.06 Impact Factor
Show more